Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002971 · ClinicalTrials.gov registry record · Phase 1
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002971 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
The verdict
NCT00002971, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of O(6)-benzylguanine given before surgery to patients who have malignant glioma.
Interventions
- DRUG O6-benzylguanine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-06-19 |
| Est. Completion | 2009-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002971
The ClinicalTrials.gov registry entry for NCT00002971 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which O6-benzylguanine is the first listed.
NCT00002971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002971 about?
NCT00002971 is a clinical study titled "O(6)-Benzylguanine in Treating Patients With Malignant Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of O(6)-benzylguanine given before surgery to patients who have malignant glioma.
What is the current status of trial NCT00002971?
This trial is currently completed. It is a Phase 1 study. The study started on 1997-06-19. Estimated completion is 2009-01-01.
What interventions are being tested in trial NCT00002971?
The interventions under investigation include: O6-benzylguanine (DRUG).
Who is sponsoring clinical trial NCT00002971?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.